201 related articles for article (PubMed ID: 28584020)
1. KIT
Phung B; Kazi JU; Lundby A; Bergsteinsdottir K; Sun J; Goding CR; Jönsson G; Olsen JV; Steingrímsson E; Rönnstrand L
Mol Cancer Res; 2017 Sep; 15(9):1265-1274. PubMed ID: 28584020
[TBL] [Abstract][Full Text] [Related]
2. The D816V mutation of c-Kit circumvents a requirement for Src family kinases in c-Kit signal transduction.
Sun J; Pedersen M; Rönnstrand L
J Biol Chem; 2009 Apr; 284(17):11039-47. PubMed ID: 19265199
[TBL] [Abstract][Full Text] [Related]
3. PI3 kinase is indispensable for oncogenic transformation by the V560D mutant of c-Kit in a kinase-independent manner.
Lindblad O; Kazi JU; Rönnstrand L; Sun J
Cell Mol Life Sci; 2015 Nov; 72(22):4399-407. PubMed ID: 26040420
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib Stimulates Its Own Mechanism of Resistance by Activating a CRTC3/MITF/Bcl-2 Pathway in Melanoma with Mutant or Amplified c-Kit.
Sabbah M; Krayem M; Najem A; Sales F; Miller W; Del Rincon S; Awada A; Ghanem GE; Journe F
Mol Cancer Res; 2021 Jul; 19(7):1221-1233. PubMed ID: 33741716
[TBL] [Abstract][Full Text] [Related]
5. C-KIT signaling depends on microphthalmia-associated transcription factor for effects on cell proliferation.
Phung B; Sun J; Schepsky A; Steingrimsson E; Rönnstrand L
PLoS One; 2011; 6(8):e24064. PubMed ID: 21887372
[TBL] [Abstract][Full Text] [Related]
6. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
Gleixner KV; Mayerhofer M; Cerny-Reiterer S; Hörmann G; Rix U; Bennett KL; Hadzijusufovic E; Meyer RA; Pickl WF; Gotlib J; Horny HP; Reiter A; Mitterbauer-Hohendanner G; Superti-Furga G; Valent P
Blood; 2011 Aug; 118(7):1885-98. PubMed ID: 21680801
[TBL] [Abstract][Full Text] [Related]
7. The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V.
Agarwal S; Kazi JU; Mohlin S; Påhlman S; Rönnstrand L
Oncogene; 2015 Aug; 34(35):4581-90. PubMed ID: 25435369
[TBL] [Abstract][Full Text] [Related]
8. D816V mutation in the KIT gene activation loop has greater cell-proliferative and anti-apoptotic ability than N822K mutation in core-binding factor acute myeloid leukemia.
Omori I; Yamaguchi H; Miyake K; Miyake N; Kitano T; Inokuchi K
Exp Hematol; 2017 Aug; 52():56-64.e4. PubMed ID: 28506695
[TBL] [Abstract][Full Text] [Related]
9. A conditional zebrafish MITF mutation reveals MITF levels are critical for melanoma promotion vs. regression in vivo.
Lister JA; Capper A; Zeng Z; Mathers ME; Richardson J; Paranthaman K; Jackson IJ; Elizabeth Patton E
J Invest Dermatol; 2014 Jan; 134(1):133-140. PubMed ID: 23831555
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia and MITF regulate KIT oncogenic properties in melanocytes.
Laugier F; Delyon J; André J; Bensussan A; Dumaz N
Oncogene; 2016 Sep; 35(38):5070-7. PubMed ID: 26973244
[TBL] [Abstract][Full Text] [Related]
11. Microphthalmia-associated transcription factor controls the DNA damage response and a lineage-specific senescence program in melanomas.
Giuliano S; Cheli Y; Ohanna M; Bonet C; Beuret L; Bille K; Loubat A; Hofman V; Hofman P; Ponzio G; Bahadoran P; Ballotti R; Bertolotto C
Cancer Res; 2010 May; 70(9):3813-22. PubMed ID: 20388797
[TBL] [Abstract][Full Text] [Related]
12. Post-translational modification of HINT1 mediates activation of MITF transcriptional activity in human melanoma cells.
Motzik A; Amir E; Erlich T; Wang J; Kim BG; Han JM; Kim JH; Nechushtan H; Guo M; Razin E; Tshori S
Oncogene; 2017 Aug; 36(33):4732-4738. PubMed ID: 28394346
[TBL] [Abstract][Full Text] [Related]
13. Novel thiazole amine class tyrosine kinase inhibitors induce apoptosis in human mast cells expressing D816V KIT mutation.
Jin Y; Ding K; Wang D; Shen M; Pan J
Cancer Lett; 2014 Oct; 353(1):115-23. PubMed ID: 25088577
[TBL] [Abstract][Full Text] [Related]
14. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
Pedersen M; Rönnstrand L; Sun J
Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
[TBL] [Abstract][Full Text] [Related]
15. Src-like-adaptor protein (SLAP) differentially regulates normal and oncogenic c-Kit signaling.
Kazi JU; Agarwal S; Sun J; Bracco E; Rönnstrand L
J Cell Sci; 2014 Feb; 127(Pt 3):653-62. PubMed ID: 24284075
[TBL] [Abstract][Full Text] [Related]
16. Mitf regulation of Dia1 controls melanoma proliferation and invasiveness.
Carreira S; Goodall J; Denat L; Rodriguez M; Nuciforo P; Hoek KS; Testori A; Larue L; Goding CR
Genes Dev; 2006 Dec; 20(24):3426-39. PubMed ID: 17182868
[TBL] [Abstract][Full Text] [Related]
17. GLI2 and M-MITF transcription factors control exclusive gene expression programs and inversely regulate invasion in human melanoma cells.
Javelaud D; Alexaki VI; Pierrat MJ; Hoek KS; Dennler S; Van Kempen L; Bertolotto C; Ballotti R; Saule S; Delmas V; Mauviel A
Pigment Cell Melanoma Res; 2011 Oct; 24(5):932-43. PubMed ID: 21801332
[TBL] [Abstract][Full Text] [Related]
18. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.
Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M
Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996
[TBL] [Abstract][Full Text] [Related]
19. Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression.
Bonet C; Luciani F; Ottavi JF; Leclerc J; Jouenne FM; Boncompagni M; Bille K; Hofman V; Bossis G; Marco de Donatis G; Strub T; Cheli Y; Ohanna M; Luciano F; Marchetti S; Rocchi S; Birling MC; Avril MF; Poulalhon N; Luc T; Hofman P; Lacour JP; Davidson I; Bressac-de Paillerets B; Ballotti R; Marine JC; Bertolotto C
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376192
[TBL] [Abstract][Full Text] [Related]
20. Identification of a small molecule that downregulates MITF expression and mediates antimelanoma activity in vitro.
Cheng C; Yang HW; Shang JF; Li WW; Sun QZ; Chen X; Cao ZX; Yao SH; Yang SY
Melanoma Res; 2016 Apr; 26(2):117-24. PubMed ID: 26684062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
